Early diagnosis and treatment by newborn screening ( NBS ) or family history is associated with improved visual outcomes for long‐chain 3‐hydroxyacylCoA dehydrogenase deficiency ( LCHADD ) chorioretinopathy
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Melanie B Gillingham und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Neonatal Screening, Early Diagnosis, Visual Acuity, Lipid Metabolism, Inborn Errors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NICHD NIH HHS, National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Long chain 3‐hydroxyacyl‐CoA dehydrogenase (LCHADD) is the only fatty acid oxidation disorder to develop a progressive chorioretinopathy resulting in vision loss; newborn screening (NBS) for this disorder began in the United States around 2004. We compared visual outcomes among 40 participants with LCHADD or trifunctional protein deficiency diagnosed symptomatically to those who were diagnosed via NBS or a family history. Participants completed ophthalmologic testing including measures of visual acuity, electroretinograms (ERG), fundal imaging, contrast sensitivity, and visual fields. Records were reviewed to document medical and treatment history. Twelve participants presented symptomatically with hypoglycemia, failure to thrive, liver dysfunction, cardiac arrest, or rhabdomyolysis. Twenty eight were diagnosed by NBS or due to a family history of LCHADD. Participants diagnosed symptomatically were older but had similar percent males and genotypes as those diagnosed by NBS. Treatment consisted of fasting avoidance, dietary long‐chain fat restriction, MCT, C7, and/or carnitine supplementation. Visual acuity, rod‐ and cone‐driven amplitudes on ERG, contrast sensitivity scores, and visual fields were all significantly worse among participants diagnosed symptomatically compared to NBS. In mixed‐effects models, both age and presentation (symptomatic vs. NBS) were significant independent factors associated with visual outcomes. This suggests that visual outcomes were improved by NBS, but there was still lower visual function with advancing age in both groups. Early diagnosis and treatment by NBS is associated with improved visual outcomes and retinal function compared to participants who presented symptomatically. Despite the impact of early intervention, chorioretinopathy was greater with advancing age, highlighting the need for novel treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
- OHSU-PSU School of Public Health, Biostatistics, Oregon Health & Science University, Portland, Oregon, USA.
- Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.
- Division of Genetic and Genomic Medicine, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Melanie B Gillingham
Förderung
- NCATS NIH HHS
- NICHD NIH HHS
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Center for Advancing Translational Sciences
Zitieren
APA
Gillingham, M. B., Choi, D., Gregor, A., Wongchaisuwat, N., Black, D., Scanga, H. L., Nischal, K. K., Sahel, J. A., Arnold, G., Vockley, J., Harding, C. O., & Pennesi, M. E. (2024). Early diagnosis and treatment by newborn screening ( NBS ) or family history is associated with improved visual outcomes for long‐chain 3‐hydroxyacylCoA dehydrogenase deficiency ( LCHADD ) chorioretinopathy. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12738
Vancouver
Gillingham MB, Choi D, Gregor A, Wongchaisuwat N, Black D, Scanga HL, et al. Early diagnosis and treatment by newborn screening ( NBS ) or family history is associated with improved visual outcomes for long‐chain 3‐hydroxyacylCoA dehydrogenase deficiency ( LCHADD ) chorioretinopathy. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12738
BibTeX
@article{Gillingham2024,
author = {Gillingham, Melanie B and Choi, Dongseok and Gregor, Ashley and Wongchaisuwat, Nida and Black, Danielle and Scanga, Hannah L and Nischal, Ken K and Sahel, Jose-Alain and Arnold, Georgianne and Vockley, Jerry and Harding, Cary O and Pennesi, Mark E},
title = {Early diagnosis and treatment by newborn screening ( NBS ) or family history is associated with improved visual outcomes for long‐chain 3‐hydroxyacylCoA dehydrogenase deficiency ( LCHADD ) chorioretinopathy},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12738}
}
EUVIMED